TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06439355

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting blood test
Description: metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fasting blood test
Description: metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fasting blood test
Description: metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subject interview
Description: socio-demographic data, medical and family history, treatment taken

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject interview
Description: socio-demographic data, medical and family history, treatment taken

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject interview
Description: socio-demographic data, medical and family history, treatment taken

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor assessment
Description: MDS-UPDRS scale PART III

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor assessment
Description: MDS-UPDRS scale PART III

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor assessment
Description: MDS-UPDRS scale PART III

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive assessment
Description: MoCA and MMSE scales

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment
Description: MoCA and MMSE scales

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment
Description: MoCA and MMSE scales

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional assessment
Description: anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional assessment
Description: anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)
Study: NCT06544317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training
Description: All children received a series of 90-minute sessions 3 times a week for 8 weeks of after-school physical training. Each session began with a warm-up (20 min), three or four tasks related to the skill to be developed (aerobic training, resistance training, other activities designed to improve motor skills and balance, stretching and flexibility activities and core strength and posture exercises; 60 min) and a cool-down (10 min). Children were divided into six groups, with the number of children in each group ranging from eight to twelve.
Study: NCT04987034

Intervention type: DEVICE
Intervention: EchoTip® Insight™
Description: Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
Study: NCT05302271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN
Description: AAVrh.10hFXN will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN
Description: AAVrh.10hFXN will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN
Description: AAVrh.10hFXN will be administered intravenously.
Study: NCT06544317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical training
Description: All children received a series of 90-minute sessions 3 times a week for 8 weeks of after-school physical training. Each session began with a warm-up (20 min), three or four tasks related to the skill to be developed (aerobic training, resistance training, other activities designed to improve motor skills and balance, stretching and flexibility activities and core strength and posture exercises; 60 min) and a cool-down (10 min). Children were divided into six groups, with the number of children in each group ranging from eight to twelve.
Study: NCT04342923

Intervention type: OTHER
Intervention: No intervention
Description: Blood analysis
Study: NCT06541158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in a CAB

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive PAF pamphlet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promotion and Care
Description: Receive the TRACT program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: Receive transportation awareness brief video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06439355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional assessment
Description: anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)
Study: NCT06541158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06424171

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac and brain magnetic resonance imaging.
Description: Cardiac magnetic resonance imaging with analysis using 4D flow. Brain magnetic resonance imaging to detect strokes, including microvascular strokes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac and brain magnetic resonance imaging.
Description: Cardiac magnetic resonance imaging with analysis using 4D flow. Brain magnetic resonance imaging to detect strokes, including microvascular strokes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac and brain magnetic resonance imaging.
Description: Cardiac magnetic resonance imaging with analysis using 4D flow. Brain magnetic resonance imaging to detect strokes, including microvascular strokes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac and brain magnetic resonance imaging.
Description: Cardiac magnetic resonance imaging with analysis using 4D flow. Brain magnetic resonance imaging to detect strokes, including microvascular strokes.
Study: NCT05566704

Intervention type: DEVICE
Intervention: Modulus ALIF System
Description: The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
Study: NCT05838443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation
Description: Neurofeedback-assisted, technology-supported mindfulness via EEG-supported device delivered individually without the need for a facilitator or travel to training site. The device allows noninvasive neural activity recording from frontal and posterior brain regions. A dedicated smartphone application uses the EEG data to provide real-time adaptive feedback-modulating natural sounds to prompt user awareness of mind-wandering and intentional return to present experience. A smartphone app will guide patients through attention and focus on breath exercises. Patients will hear their distracted mind as the wind. Wind becomes stronger if their mind wanders, prompting patient's awareness of their wandering mind and guiding the patient back to focusing on their breath without judgment of how they are doing. Patients will be asked to practice mindfulness using the device for 20 minutes per day for 4 sessions prior to surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider-directed mindfulness
Description: Patients will receive mental health support by a licensed social work provider who is trained in mindfulness through four 20-minute telehealth sessions. Patients will be taught cognitive behavioral therapy (CBT) techniques to reduce pain catastrophizing and increase coping efficacy, the clinician will review patient's current sleep routine and teach concepts and strategies to improve sleep. Patients will be guided through mindfulness and meditation exercises to improve pain and mood coping. Mindfulness-based instructions takes patients through quieting their mind by focusing on breath, expanding focus (i.e., at the tip of their nose full flow of the breath), with emphasis on acknowledgement of arising thoughts/emotions without judgement or emotional reaction, and return attention back to breath sensation. Principles of CBT and mindfulness will be reiterated at subsequent sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Care
Description: Control group, as defined by our institution's standard preoperative care for given procedure, which does not include psychological preparation.
Study: NCT05105542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor
Description: The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor
Description: The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET scanner with high sensitivity and resolution available for human brain imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: PET scanner with high sensitivity and resolution available for human brain imaging
Study: NCT04868656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Strategy: Foundational Support
Description: The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational support), will be sufficient for some but not all hospitals to successfully incorporate STRIDE into routine practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Strategy: Enhanced Support
Description: The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We posit that monitoring hospitals' progress and adding, for hospitals with low adoption, higher intensity strategies (defined as Enhanced Support) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
Study: NCT06374394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: 1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA investigational vaccine
Description: 1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.
Study: NCT06439355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taste tests
Description: Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste tests
Description: Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taste tests
Description: Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)
Study: NCT06374394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine
Description: 1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 mRNA vaccine
Description: 1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.
Study: NCT05655754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: anesthesia during ECT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol
Description: anesthesia during ECT
Study: NCT05473923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.
Description: Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
Study: NCT06198023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: The educational intervention is an 8-session series of informational presentations about brain function and altered social processing related to eating disorders. Participants will receive a reflective prompt to complete as homework and will have an opportunity to discuss their responses during the following session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive
Description: The interactive intervention is an 8-session series of experiential art therapy tasks followed by education about social processing. Participants will complete the tasks as a group or in small teams. Afterward, they will be encouraged to discuss their thoughts and feelings related to their experience. The educational component will include a homework assignment that participants will have the opportunity to discuss at the following session.
Study: NCT05398302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image Guided Biopsy
Description: Undergo image-guided biopsy
Study: NCT05032001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Description: Oral antidiabetic treatment during twelve weeks
Study: NCT05905523

Intervention type: OTHER
Intervention: Assessing prewriting skills in children
Description: In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development

Intervention type: OTHER
Intervention: Assessing prewriting skills in children
Description: In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development

Intervention type: OTHER
Intervention: Assessing prewriting skills in children
Description: In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development

Intervention type: OTHER
Intervention: Assessing prewriting skills in children
Description: In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development

Intervention type: OTHER
Intervention: Assessing prewriting skills in children
Description: In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development
Study: NCT05819086

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rate Emotional Response
Description: Participants will view their assigned video package, and will be asked to rate their emotional response to the message

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rate Emotional Response
Description: Participants will view their assigned video package, and will be asked to rate their emotional response to the message

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rate Emotional Response
Description: Participants will view their assigned video package, and will be asked to rate their emotional response to the message

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rate Emotional Response
Description: Participants will view their assigned video package, and will be asked to rate their emotional response to the message

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rate Impact of Message
Description: Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rate Impact of Message
Description: Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rate Impact of Message
Description: Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rate Impact of Message
Description: Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
Study: NCT04839523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exufiber
Description: A sterile nonwoven wound dressing made from highly absorbent PVA fibers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exufiber Ag+
Description: A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
Study: NCT06531941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg of MBX 2109 once-weekly by subcutaneous injection
Description: Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients who received Placebo in the Phase 2 MBX-2H1002 study, will initiate treatment with 400 µg subcutaneous MBX 2109 once-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
Description: Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients treated with MBX 2109 in the Phase 2 MBX-2H1002 study will continue at the screening visit in the extension study on the same dose they were receiving at the Week 11 Visit in Study MBX-2H1002.~The maximum allowed dose is 1600 μg weekly administered subcutaneously in the abdomen, rotating injection sites. Doses of MBX 2109 study drug greater than 1000 μg will be administered subcutaneously in two separate, equal injections.
Study: NCT05857930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85
Description: OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
Study: NCT05032001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Description: Oral antidiabetic treatment during twelve weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Description: Oral antidiabetic treatment during twelve weeks
Study: NCT06097676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam 2 mg
Description: Oral dose of alprazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg
Description: Oral dose of GE-IR 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg
Description: Oral dose of GE-IR 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
Description: Oral dose of GE-IR 700 mg
Study: NCT05302271

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN
Description: AAVrh.10hFXN will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.